<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501565</url>
  </required_header>
  <id_info>
    <org_study_id>FP2011/01</org_study_id>
    <secondary_id>2011-003219-53</secondary_id>
    <nct_id>NCT01501565</nct_id>
  </id_info>
  <brief_title>Analgesic Efficacy of Ultrasound-guided Transverse-abdominal Plain Blockade in Urological Surgery</brief_title>
  <official_title>Ultrasound-guided Analgesic Transverse Abdominal Plain Blockade in the Multimodal Pain Management for Laparoscopic Urological Surgery. Analgesic Efficacy Assessment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacio Puigvert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacio Puigvert</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare pain level (according to numerical score)at 4, 8, 12
      and 24 postoperative hours between patients under transverse abdominal plain blockade (TAP)
      and patients under conventional analgesia. Also the opioid consumption is assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain level</measure>
    <time_frame>Change in pain from admittance to 24 hours postoperatively</time_frame>
    <description>Pain is assessed by numerical scale (0 to 10) where 0 is no pain and 10 is the most intense pain possible. Pain will be assessed at 4, 6 , 8, 12 and 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption as a rescue therapy</measure>
    <time_frame>within 24 postoperative hours</time_frame>
    <description>Analgesic consumption: morphine in miligrams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative nausea and vomiting (PONV) related to therapy</measure>
    <time_frame>within 24 postoperative hours</time_frame>
    <description>Assessment of PONV incidence and antiemetic drugs consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of urethral/bladder spasm</measure>
    <time_frame>within 24 postoperative hours</time_frame>
    <description>Pain due to bladder catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of oral intake tolerance</measure>
    <time_frame>within 24 postoperative hours</time_frame>
    <description>Assessment at 6 postoperative hours for liquids, and solid food at 24 postoperative hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>within 24 postoperative hours</time_frame>
    <description>Assessed by ordinal scale: Very pleased/Pleased/little pleased/little unpleased/unpleased/very unpleased</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard analgesic therapy: iv Metamizol 2 g q8h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transverse abdominal plain (TAP) blockade with local anesthetic: Bupivacaine chlorhydrate 0.25% adjusted by weight and type of surgery. Maximum dose: 150 mg of bupivacaine.
Two approaches are done: 1)Posterior TAP: the needle insertion point is cephalad to the iliac crest, behind the midaxillary line. The needle is inserted under ultrasound guidance in plane. Local anesthetics is deposited between the internal oblique and transversus abdominis muscles, 2)Subcostal TAP: the needle is inserted ultrasound guided perpendicularly to abdominal wall, directed parallel to the costal margin but oblique to the sagittal plane. Local anesthestic is deposited between transversus abdominis and the rectus abdominis muscles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Postoperative transverse abdominal plain (TAP) blockade</intervention_name>
    <description>Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.</description>
    <arm_group_label>TAP</arm_group_label>
    <other_name>Buivacaine: Inibsicain (R) 0.25% (INIBSA, S.A.)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 yrs.

          -  Patients undergo laparoscopic urologic surgery

          -  Physical status ASA &lt; 3

          -  Surgical procedure without complications

          -  Signed informed consent

        Exclusion Criteria:

          -  Allergy to bupivacaine chlorhydrate

          -  Patients with chronic pain treatment

          -  Alcoholism

          -  Decompensated hepatic disease

          -  Coagulation disorders

          -  BMI &gt; 35

          -  Patient involved in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Francisco Mayoral, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Puigvert (IUNA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundació Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>November 15, 2012</last_update_submitted>
  <last_update_submitted_qc>November 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacio Puigvert</investigator_affiliation>
    <investigator_full_name>Juan Francisco Mayoral Farre</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Postoperative pain</keyword>
  <keyword>Transverse abdominal blockade</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Urology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

